FDA Approves Brentuximab Vedotin with Lenalidomide and Rituximab for Relapsed or Refractory Large B-Cell Lymphoma By Ogkologos - March 27, 2025 675 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ECHELON-3 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Adding Capivasertib to Fulvestrant Results in Longer PFS in Patients with... June 5, 2023 At NCI, A Robust and Rapid Response to the COVID-19 Pandemic April 17, 2020 Cemiplimab Outperforms Investigator’s Choice Chemotherapy in the Second-Line Setting for Recurrent/Metastatic... May 12, 2021 Bus Driver Finds Out Teen With Cancer Can’t Afford Prom &... June 19, 2019 Load more HOT NEWS New on NCI’s Websites for December 2023 Metformin May Affect Risk of Breast Cancer in Women with Type... ESMO’s Expert Consensus: Do Not Discontinue or Delay Cancer Treatment That... Cancer in My Community: Developing Pediatric Palliative and Supportive Care in...
